Key result
A protocol was developed for high-precision detection of single-nucleotide variants using a Cas12a-based approach and the ARTEMIS algorithm on synthetic DNA, cell line cfDNA, and liquid biopsies.
Why the study?
CRISPR-based diagnostics offer promising tools for rapid and cost-effective genetic testing, but achieving single-nucleotide fidelity remains a challenge.
Provides a protocol for high-precision detection of single-nucleotide variants using a Cas12a-based approach and the ARTEMIS algorithm.
Advances lab-based SNV detection; leaves open clinical translation pending validation.
CRISPR-based diagnostics (CRISPRdx) offer promising tools for rapid and cost-effective genetic testing, but achieving single-nucleotide fidelity remains a challenge. Here, we present a protocol for high-precision detection of single-nucleotide variants (SNVs) using a Cas12a-based approach. We describe how to apply our publicly available ARTEMIS algorithm to identify targetable SNVs, design optimized CRISPR RNAs (crRNAs), and perform fluorescence-based CRISPRdx assays on synthetic DNA, cell line-derived cell-free DNA (cfDNA), and liquid biopsy samples. For complete details on the use and execution of this protocol, please refer to Kohabir et al. 1 • Use ARTEMIS to design crRNAs optimized for Cas12a-based SNV detection • Validate crRNA specificity using synthetic DNA and fluorescence-based assays • Assess performance on cfDNA derived from cultured cell line models • Evaluate CRISPR-based diagnostics on liquid biopsy-derived cfDNA samples Publisher’s note: Undertaking any experimental protocol requires adherence to local institutional guidelines for laboratory safety and ethics. CRISPR-based diagnostics (CRISPRdx) offer promising tools for rapid and cost-effective genetic testing, but achieving single-nucleotide fidelity remains a challenge. Here, we present a protocol for high-precision detection of single-nucleotide variants (SNVs) using a Cas12a-based approach. We describe how to apply our publicly available ARTEMIS algorithm to identify targetable SNVs, design optimized CRISPR RNAs (crRNAs), and perform fluorescence-based CRISPRdx assays on synthetic DNA, cell line-derived cell-free DNA (cfDNA), and liquid biopsy samples.
No takes yet. Share an insight, caveat, or question.
Kohabir et al. (2025) studied Single-nucleotide variants (SNVs). CRISPR-Cas12a-based SNV detection was evaluated. A protocol was developed for high-precision detection of single-nucleotide variants using a Cas12a-based approach and the ARTEMIS algorithm on synthetic DNA, cell line cfDNA, and liquid biopsies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: